B. Riley initiated coverage on shares of Amyris (NASDAQ:AMRS) in a report released on Thursday morning, MarketBeat.com reports. The firm issued a buy rating and a $8.00 price objective on the biotechnology company’s stock.

Several other research analysts have also recently issued reports on the stock. HC Wainwright set a $15.00 price objective on shares of Amyris and gave the company a buy rating in a report on Wednesday, November 29th. Zacks Investment Research cut shares of Amyris from a buy rating to a hold rating in a report on Monday, October 23rd. Cowen reiterated a hold rating and issued a $4.00 price objective on shares of Amyris in a report on Wednesday, November 29th. Finally, ValuEngine cut shares of Amyris from a sell rating to a strong sell rating in a report on Friday, December 1st. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the stock. The stock has a consensus rating of Hold and a consensus price target of $7.69.

Amyris (NASDAQ:AMRS) opened at $5.19 on Thursday. The company has a quick ratio of 0.82, a current ratio of 0.92 and a debt-to-equity ratio of -0.78. The stock has a market cap of $222.91, a P/E ratio of -0.92 and a beta of 0.16. Amyris has a 1-year low of $1.86 and a 1-year high of $10.65.

Amyris (NASDAQ:AMRS) last posted its quarterly earnings data on Tuesday, November 14th. The biotechnology company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.77) by ($0.04). The firm had revenue of $24.20 million for the quarter, compared to analyst estimates of $36.30 million. Amyris’s quarterly revenue was down 8.8% on a year-over-year basis. During the same period in the previous year, the business earned ($0.07) EPS. analysts anticipate that Amyris will post -3.32 EPS for the current fiscal year.

In related news, insider John Melo sold 10,776 shares of the stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $4.68, for a total transaction of $50,431.68. Following the completion of the sale, the insider now directly owns 83,172 shares of the company’s stock, valued at $389,244.96. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 11.30% of the stock is owned by corporate insiders.

A number of hedge funds have recently added to or reduced their stakes in AMRS. Bank of New York Mellon Corp lifted its stake in Amyris by 16.3% during the second quarter. Bank of New York Mellon Corp now owns 32,768 shares of the biotechnology company’s stock valued at $104,000 after purchasing an additional 4,603 shares during the last quarter. Carl Domino Inc acquired a new stake in Amyris during the third quarter valued at approximately $182,000. Creative Planning acquired a new stake in Amyris during the fourth quarter valued at approximately $188,000. KBC Group NV lifted its stake in Amyris by 228.4% during the third quarter. KBC Group NV now owns 60,154 shares of the biotechnology company’s stock valued at $192,000 after purchasing an additional 41,834 shares during the last quarter. Finally, Tanaka Capital Management Inc. lifted its stake in Amyris by 72.0% during the third quarter. Tanaka Capital Management Inc. now owns 528,549 shares of the biotechnology company’s stock valued at $1,691,000 after purchasing an additional 221,295 shares during the last quarter. 22.84% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This article was first reported by Daily Political and is owned by of Daily Political. If you are accessing this article on another publication, it was illegally copied and republished in violation of international copyright and trademark law. The original version of this article can be accessed at https://www.dailypolitical.com/2018/01/28/b-riley-begins-coverage-on-amyris-amrs.html.

Amyris Company Profile

Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.

Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.